IN THE NEWS
Decode Health Selected As 2023 Best In Business Awards Finalist By Nashville Business Journal
Decode Health, a precision medicine analytics company, was recently announced as a 2023 Best in Business Awards finalist by Nashville Business Journal (NBJ).
Decode Health and Briya Announce Partnership to Advance Precision Medicine through Decentralized Data Exchange
Decode Health, a Nashville based precision medicine analytics company, and Briya, an end-to-end decentralized data exchange platform also based in Nashville with offices in Tel Aviv, today announced a partnership to accelerate innovation projects that seek to improve patient outcomes and advance precision medicine.
Decode Health: Advancing Precision Medicine to Improve Lives
Current methods of managing healthcare are unsustainable, with chronic disease treatment alone putting a $4 trillion annual strain on the U.S. economy. Healthcare professionals across the board agree that earlier diagnosis, better preventative care, and improved disease management will significantly reduce those costs while improving the lives of millions of Americans. In a healthcare landscape rapidly moving towards personalized patient care, precision medicine offers a unique solution.
OUR ABSTRACTS
Application of an advanced data analytics platform leveraging artificial intelligence to identify RNA biomarkers
November 2023 – Poster Presentation
Long, non-coding RNA signatures to distinguish relapsing-remitting and progressive forms of multiple sclerosis
October 2023 – Poster Presentation
OUR PUBLICATIONS
RECENT PODCASTS
WEBINARS
Next-generation RNA sequencing unlocks the discovery of novel candidate biomarkers for diagnostic and therapeutic applications, but reproducibility is a key challenge in biomarker discovery programs. Integrating multi-faceted quality control (QC) steps can improve design decisions and enhance the confidence and reliability of results. This webinar will demonstrate how a comprehensive QC framework supports a disease-agnostic biomarker discovery program to identify biologically relevant candidate biomarkers of complex disease and how this framework can be adapted for total RNA sequencing of whole blood, plasma, and serum samples.
